Bibliografia:

• Abdul-Ghani MA, Norton L, Defronzo RA. Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.
  Curr Diab Rep 2012;12:230-38
• Adler AI, Shaw EJ, Stokes T, Ruiz F; Guideline Development Group. Newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance.
  BMJ 2009;338:b1668
• Ahrén B, Gomis R, Standl E, Mills D, Schweizer A. Twelve and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes.
  Diabetes Care 2004;12:2874-80
• Anderson M, Powell J, Campbell KM, Taylor JR. Optimal management of type 2 diabetes in patients with increased risk of hypoglycemia.
  Diabetes Metab Syndr Obes 2014;7:85-94
• Aronson R. The role of comfort and discomfort in insulin therapy. Diabetes Technol Ther. 2012;14(8):741-7
• Banerji MA, Purkayastha D, Francis BH. Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study.
  Diabetes Res Clin Pract 2010;90:182-90
• Bergman AJ, Cote J, Yi B, Marbury T, Swan SK, Smith W, Gottesdiener K, Wagner J, Herman GA.Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor.
  Diabetes Metab 2013;39:445-63
• Blanco M. Hernández M.T. Strauss K.W., Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes.
  Diabetes Care 2007;30:1862-64
• Bolinder J, Ljunggren Ö, Kullberg J, Johansson L, Wilding J, Langkilde AM, Sugg J, Parikh S. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
  J Clin Endocrinol Metab 2012;97:1020-31
• Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.
  Diabetes Care 2007;4:890-95
• Brazg R, Xu L, Dalla Man C, Cobelli C, Thomas K, Stein PP. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and b-cell function in patients with type 2 diabetes.
  Diabetes Obes Metab 2007;2:186-93
• Buckwald H., Estok R, Fahrbach K, Banel D, Jensen MD, Pories BJ, Bantle JP, Sledge I. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis.
  Am J Med 2009;122:248-56
• Campbell IW and Howlett HCS. Worldwide experience of metformin as an effective glucose lowering agent: a metanalysis.
  Diabetes Metab Rev 1995;11(Suppl 1):S57-S62
• Ceriello A, Gallo M, Armentano V, Perriello G, Gentile S, De Micheli A, on behalf of the Associazione Medici Diabetologi. Personalizing Treatment in Type 2 Diabetes: A Self-Monitoring of Blood Glucose Inclusive Innovative Approach.
  Diabetes Technol Ther 2012;14:373-78
• Ceriello A, Gallo M, Candido R, De Micheli A, Esposito K, Gentile S, Medea G. Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach.
  Pharmgenomics Pers Med 2014;7:129-136 - Video ​abstract
• Ceriello A, Gallo M, Gentile S, Giorda CB, De Micheli A, on behalf of Associazione Medici Diabetologi (AMD). To what extent is the new position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) ‘personalised’? (letter).
  Diabetologia 2012;55:2853-5
• Chan NN, Brain HP, Feher MD, Metformin-associated lactic acidosis: a rare or very rare clinical entity?
  Diabet Med 1999;4:273-81
• Chan JC, Scott R, Arjona Ferreira JC, Sheng D, Gonzalez E, Davies MJ, Stein PP, Kaufman KD, Amatruda JM, Williams-Herman D. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency.
  Diabetes Obes Metab 2008;10:545-55
• Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
  Diabetes Care 2006;12:2638-43
• DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, Ravichandran S, Chen RS; Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone.
  Diabetes Care 2009;32:1649-55
• DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
  Diabetes Care 2005;5:1092-100
• Del Prato S. Megatrials in type 2 diabetes. From excitement to frustration?
  Diabetologia 2009;52:1219-26
• Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes.
  N Engl J Med 2009;360:129-39
• Dunning T, Sinclair A, Colagiuri S. New IDF Guideline for managing type 2 diabetes in older people.
  Diabetes Res Clin Pract 2014;103:538-40
• Durán A, Martín P, Runkle I, Pérez N, Abad R, Fernández M, Del Valle L, Sanz MF, Calle-Pascual AL. Benefits of self-monitoring blood glucose in the management of new-onset Type 2 diabetes mellitus: the St Carlos Study, a prospective randomized clinic-based interventional study with parallel groups.
  J Diabetes 2010 Sep;2(3):203-11
• Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.
  Clin Ther 2000;12:1395-409
• Eldor R, Raz I. The Individualized Target HbA_1c: A New Method for Improving Macrovascular Risk and Glycemia Without Hypoglycemia and Weight Gain.
  Rev Diabet Stud 2009;6:6-12
• EMA, European Medicines Agency.
• Esposito K, Gentile S, Candido R, De Micheli A, Gallo M, Medea G, Ceriello A; Associazione Medici Diabetologi. Management of hyperglycemia in type 2 diabetes: evidence and uncertainty.
  Cardiovasc Diabetol 2013;12:81
• Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.
  Nat Rev Endocrinol 2012;8:495-502
• Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.
  Diabetes Care 2003;8:2370-77
• Fineman MS, Cirincione BB, Maggs D, et al. GLP-1 based therapies: differential effects on fasting and postprandial glucose.
  Diabetes Obes Metab 2012;14:675-688
• Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
  JAMA 2000;283:1695-702
• Frid A, Hirsch L, Gaspar R, Hicks D, Kreugel G, Liersch J, Letondeur C, Sauvanet JP, Tubiana-Rufi N, Strauss K; Scientific Advisory Board for the Third Injection Technique Workshop. New injection recommendations for patients with diabetes. Scientific Advisory Board for the Third Injection Technique Workshop.
  Diabetes Metab 2010;36(Suppl 2):S3-18
• Gallo M, Candido R, De Micheli A, Esposito K, Gentile S, Ceriello A; Associazione Medici Diabetologi. Acarbose vs metformin for new-onset type 2 diabetes.
  Lancet Diabetes Endocrinol 2014;2:104
• Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.
  Diabetes Obes Metab 2007;2:166-74
• Gentile S, Agrusta M, Guarino G, Carbone L, Cavallaro V, Carucci I, Strollo F.Metabolic consequences of incorrect insulin administration techniques in aging subjects with diabetes.
  Acta Diabetol 2011;48:121-5
• Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group. Effects of intensive glucose lowering in type 2 diabetes.
  
N Engl J Med 2008;358:2545-59
• Gibney MA, Arce CH, Byron KJ, Hirsch LJ. Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations.
  
Curr Med Res Opin 2010;26:1519-30
• Giorda CB, Nada E, Tartaglino B. Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature.
  
Endocrine 2014;46:406-19
• Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Ceriello A, Esposito K. Efficacy of insulin analogs in achieving the hemoglobin A1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.
  Diabetes Care 2011;34:510-7
• Graefe-Mody U, Friedrich C, Port A, Ring A, Retlich S, Heise T, Halabi A, Woerle HJ. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin.
  Diabetes Obes Metab 2011;13:939-46
• Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams- Herman DE; Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.
  Diabetes Care 2007;8:1979-87
• Hansen B, Matytsina I. Insulin administration: selecting the appropriate needle and individualizing the injection technique.
  Expert Opin Drug Deliv 2011;8:1395-406
• Harrower ADJ. Comparison of efficacy, secondary failure rate, and complications of sulfonylureas.
  Diabetes Complications 1994;8:201-3
• Hermann LS, Schersten B, and Melander A, Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination.
  Diabetic Medicine 1994;11:953-60
• International Diabetes Federation 2011 Guideline for Management of PostMeal Glucose in Diabetes. Disponibile qui
  http://www.idf.org/sites/default/files/postmeal%20glucose%20guidelines.pdf
• Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
  Diabetologia 2012;55:1577-96
• Inzucchi SE, McGuire DK. New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond.
  Circulation 2008;117:574-84
• Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.
  Diabetes Care. 2015; 38:140-9
• Jadzinsky M, Pfützner A, Paz-Pacheco E, Xu Z, Allen E, Chen R; CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.
  Diabetes Obes Metab 2009;11:611-22
• Johansen K. Efficacy of metformin in the treatment of NIDDM. Metanalysis.
  Diabetes Care 1999;22:33-37
• Jones TA, Sautter M, Van Gaal LF, Jones NP. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes.
  Diabetes Obes Metab 2003;5:163-70
• Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combinatio with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
  Am J Med 2001;1:10-17
• Kooy A, de Jager J, Lehert P, Bets D, Wulffelé MG, Donker AJM, Stehouwer CDA Long-term Effects of Metformin on Metabolism and Microvascular and Macrovascular Disease in Patients With Type 2 Di abetes Mellitus.
  Arch Intern Med 2009;6:616-25
• Kothny W, Shao Q, Groop PH, Lukashevich V. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment.
  Diabetes Obes Metab 2012, Jun 12
• Lo Presti D, Ingegnosi C, Strauss K. Skin and subcutaneous thikness at injecting sites in children with diabetes: ultrasound findings and recommendations for giving injection.
  Pediatr Diabetes 2012;13:525-33
• Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial.
  Diabetes Obes Metab 2011;13:947-54
• Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee.; LEADER Trial Investigators.Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
  N Engl J Med. 2016;375:311-22
• Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Enodcrinol 8:728-742, 2012
• Melchior WR and Jaber LA. Metformin: an antihyperglycemic agent for treatment of type II diabetes.
  Ann Pharmacother 1996;30:158-64
• Moses R, Slobodniuk R, Boyages S, Colagiuri S, Kidson W, Carter J, Donnelly T, Moffitt P, Hopkins H. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with Type 2 diabetes.
  Diabetes Care 1999;1:119-24
• Nathan DM. Thiazolidinediones for initial treatment of type 2 diabetes?
  N Engl J Med 2006;23:2477-80
• Nowicki M, Rychlik I, Haller H, Warren ML, Suchower L, Gause-Nilsson I; D1680C00007 Investigators. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment.
  Diabetes Obes Metab 2011;13:523-32
• Nowicki M, Rychlik I, Haller H, Warren M, Suchower L, Gause-Nilsson I, Schützer KM. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.
  Int J Clin Pract 2011;65:1230-39
• Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, Maggo J, Gray V, De Berardis G, Ruospo M, Natale P, Saglimbene V, Badve SV, Cho Y, Nadeau-Fredette AC, Burke M, Faruque L, Lloyd A, Ahmad N, Liu Y, Tiv S, Wiebe N, Strippoli GF. Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.
  JAMA. 2016;316:313-24
• Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
  N Engl J Med 2008;358:2560-72
• Pozzilli P, Leslie RD, Chan J, De Fronzo R, Monnier L, Raz I, Del Prato S. The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach.
  Diabetes Metab Res Rev 2010;26:239-44
• Ratner RE, Maggs D, Nielsen LL, Stonehouse AH, Poon T, Zhang B, Bicsak TA, Brodows RG, Kim DD. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus.
  Diabetes Obes Metab 2006;4:419-28
• Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM, Langdon RB, Stein PP, Alba M. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.
  Curr Med Res Opin 2008;2:537-50
• Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, Jermendy G, Campaigne BN, Kerr L, Milicevic Z, Jacober SJ. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial.
  Diabetes Care 2009;32:381-86
• Redmon JB, Bertoni AG, Connelly S, Feeney PA, Glasser SP, Glick H, Greenway F, Hesson LA, Lawlor MS, Montez M, Montgomery B; Look AHEAD Research Group. Effect of the look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes.
  Diabetes Care 2010;33:1153-58
• Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
  Clin Ther 2006;10:1556-68
• Rosenstock J, Brown A, Fischer J, Jain A, Littlejohn T, Nadeau D, Sussman A, Taylor T, Krol A, Magner J. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes.
  Diabetes Care 1998;21:2050-55
• Rosenstock J, Kim SW, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.
  Diabetes Obes Metab 2007;2:175-85
• Salpeter SR, Greyber E, Pasternak GA, Salpeter EE, Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and metanalysis.
  Arch Intern Med 2003;21:2594-602
• Scheen AJ. Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.
  Expert Opin Drug Metab Toxicol 2012;8:383-94
• Shanik MH. Intensifying insulin therapy with insulin analog premixes: transitioning from basal insulin in type 2 diabetes.
  Diabetes Technol Ther 2012;14:533-9
• Sinclair AJ, Paolisso G, Castro M, Bourdel-Marchasson I, Gadsby R, Rodriguez Mañas L; European Diabetes Working Party for Older People. European Diabetes Working Party for Older People 2011 clinical guidelines for type 2 diabetes mellitus. Executive summary.
  Diabetes Metab 2011;37(Suppl 3):S27-38
• Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects.
  N Engl J Med 2007;357:741-52
• Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association.
  Diabetes Care 2009;32:187-92
• Tayek J. SUR receptor activity vs. incidence of hypoglycaemia and cardiovascular mortality with sulphonylurea therapy for diabetics.
  Diabetes Obes Metab 2008;10:1128-1130
• Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
  JAMA 1999;281:2005-12
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).
  Lancet 1998;352:854-65
• UK Prospective Diabetes Study (UKPDS) Group. UKPDS 28: A randomised trial of efficacy of early addition of metformin in sulfonylurea treated type 2 diabetes.
  Diabetes Care 1998;1:87-92
• Van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C. Alpha‑glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and metanalysis.
  Diabetes Care 2005;1:154-63
• Vetter ML, Cardillo S, Rickels MR, Iqbal N. Narrative review: Effect of bariatric surgery on type 2 diabetes mellitus.
  Ann Intern Med 2009;150:94-103
• Washburn WN. Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents.
  Expert Opin Ther Pat 2012;22:483-94
• Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
  Health Technol Assess 2010;14:1-248
• Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, Hu Y, Zhou Z, Yan X, Tian H, Ran X, Luo Z, Xian J, Yan L, Li F, Zeng L, Chen Y, Yang L, Yan S, Liu J, Li M, Fu Z, Cheng H. Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial.
  Lancet 2008;371:1753-60
• Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, Parikh S; Dapagliflozin 006 Study Group. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.
  Ann Intern Med 2012;156:405-15
• Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators.Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
  N Engl J Med. 2015;373:2117-28